全文获取类型
收费全文 | 1693421篇 |
免费 | 126580篇 |
国内免费 | 3780篇 |
专业分类
耳鼻咽喉 | 21738篇 |
儿科学 | 55650篇 |
妇产科学 | 46200篇 |
基础医学 | 241406篇 |
口腔科学 | 48790篇 |
临床医学 | 151410篇 |
内科学 | 333605篇 |
皮肤病学 | 38667篇 |
神经病学 | 131273篇 |
特种医学 | 63925篇 |
外国民族医学 | 242篇 |
外科学 | 257347篇 |
综合类 | 38965篇 |
现状与发展 | 4篇 |
一般理论 | 531篇 |
预防医学 | 124306篇 |
眼科学 | 40198篇 |
药学 | 123702篇 |
7篇 | |
中国医学 | 4477篇 |
肿瘤学 | 101338篇 |
出版年
2021年 | 12796篇 |
2019年 | 13546篇 |
2018年 | 19975篇 |
2017年 | 15223篇 |
2016年 | 16631篇 |
2015年 | 18990篇 |
2014年 | 26258篇 |
2013年 | 37996篇 |
2012年 | 52798篇 |
2011年 | 55498篇 |
2010年 | 32815篇 |
2009年 | 30723篇 |
2008年 | 51576篇 |
2007年 | 54872篇 |
2006年 | 55317篇 |
2005年 | 52620篇 |
2004年 | 50793篇 |
2003年 | 48188篇 |
2002年 | 46418篇 |
2001年 | 91825篇 |
2000年 | 93663篇 |
1999年 | 76997篇 |
1998年 | 19735篇 |
1997年 | 17284篇 |
1996年 | 17408篇 |
1995年 | 16751篇 |
1994年 | 15299篇 |
1993年 | 14090篇 |
1992年 | 57421篇 |
1991年 | 55297篇 |
1990年 | 53001篇 |
1989年 | 50783篇 |
1988年 | 46154篇 |
1987年 | 44950篇 |
1986年 | 42248篇 |
1985年 | 40006篇 |
1984年 | 29373篇 |
1983年 | 24934篇 |
1982年 | 13914篇 |
1979年 | 25548篇 |
1978年 | 17584篇 |
1977年 | 14915篇 |
1976年 | 13887篇 |
1975年 | 14581篇 |
1974年 | 17640篇 |
1973年 | 16957篇 |
1972年 | 15688篇 |
1971年 | 14462篇 |
1970年 | 13441篇 |
1969年 | 12526篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Molnár B. Aroca S. Dobos A. Orbán K. Szabó J. Windisch P. Stähli A. Sculean A. 《Clinical oral investigations》2022,26(12):7135-7142
Clinical Oral Investigations - To evaluate t he long-term outcomes following treatment of RT 1 multiple adjacent gingival recessions (MAGR) using the modified coronally advanced tunnel (MCAT) with... 相似文献
2.
Kienbaum Peter Schaefer Maximilian S. Weibel Stephanie Schlesinger Tobias Meybohm Patrick Eberhart Leopold H. Kranke Peter 《Der Anaesthesist》2022,71(2):123-128
Die Anaesthesiologie - Auch wenn für Anästhesiologen über Jahrzehnte die Prophylaxe und Therapie postoperativer Schmerzen im Rahmen des postoperativen Patientenkomforts an vorderster... 相似文献
3.
4.
5.
6.
7.
Karl Johnson Katherine W. Saylor Isabella Guynn Karen Hicklin Jonathan S. Berg Kristen Hassmiller Lich 《Genetics in medicine》2022,24(2):262-288
PurposeUnderstanding the value of genetic screening and testing for monogenic disorders requires high-quality, methodologically robust economic evaluations. This systematic review sought to assess the methodological quality among such studies and examined opportunities for improvement.MethodsWe searched PubMed, Cochrane, Embase, and Web of Science for economic evaluations of genetic screening/testing (2013-2019). Methodological rigor and adherence to best practices were systematically assessed using the British Medical Journal checklist.ResultsAcross the 47 identified studies, there were substantial variations in modeling approaches, reporting detail, and sophistication. Models ranged from simple decision trees to individual-level microsimulations that compared between 2 and >20 alternative interventions. Many studies failed to report sufficient detail to enable replication or did not justify modeling assumptions, especially for costing methods and utility values. Meta-analyses, systematic reviews, or calibration were rarely used to derive parameter estimates. Nearly all studies conducted some sensitivity analysis, and more sophisticated studies implemented probabilistic sensitivity/uncertainty analysis, threshold analysis, and value of information analysis.ConclusionWe describe a heterogeneous body of work and present recommendations and exemplar studies across the methodological domains of (1) perspective, scope, and parameter selection; (2) use of uncertainty/sensitivity analyses; and (3) reporting transparency for improvement in the economic evaluation of genetic screening/testing. 相似文献
8.
9.
Kara S. Tanaka MD Veronica R. Andaya BA Steven W. Thorpe MD Kenneth R. Gundle MD James B. Hayden MD Yee-Cheen Duong MD Raffi S. Avedian MD David G. Mohler MD Lee J. Morse MD Melissa N. Zimel MD Richard J. O'Donnell MD Andrew Fang MD Robert Lor Randall MD Tina H. Tran BS Christin New BA Rosanna L. Wustrack MD other members of Study Group FORCE 《Journal of surgical oncology》2023,127(1):148-158
10.
Major depressive disorder and other neuropsychiatric disorders are often managed with long-term use of antidepressant medication. Fluoxetine, an SSRI antidepressant, is widely used as a first-line treatment for neuropsychiatric disorders. However, fluoxetine has also been shown to increase the risk of metabolic diseases such as non-alcoholic fatty liver disease. Fluoxetine has been shown to increase hepatic lipid accumulation in vivo and in vitro. In addition, fluoxetine has been shown to alter the production of prostaglandins which have also been implicated in the development of non-alcoholic fatty liver disease. The goal of this study was to assess the effect of fluoxetine exposure on the prostaglandin biosynthetic pathway and lipid accumulation in a hepatic cell line (H4-II-E-C3 cells). Fluoxetine treatment increased mRNA expression of prostaglandin biosynthetic enzymes (Ptgs1, Ptgs2, and Ptgds), PPAR gamma (Pparg), and PPAR gamma downstream targets involved in fatty acid uptake (Cd36, Fatp2, and Fatp5) as well as production of 15-deoxy-Δ12,14PGJ2 a PPAR gamma ligand. The effects of fluoxetine to induce lipid accumulation were attenuated with a PTGS1 specific inhibitor (SC-560), whereas inhibition of PTGS2 had no effect. Moreover, SC-560 attenuated 15-deoxy-Δ12,14PGJ2 production and expression of PPAR gamma downstream target genes. Taken together these results suggest that fluoxetine-induced lipid abnormalities appear to be mediated via PTGS1 and its downstream product 15d-PGJ2 and suggest a novel therapeutic target to prevent some of the adverse effects of fluoxetine treatment. 相似文献